報價延遲最少15分鐘:2024/12/25 01:17 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
10.87 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.51/-0.80
|
|
企業價值
948.01M
|
| 資產負債 |
|
每股賬面淨值
1.53
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/12/25 01:17 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are used to select patients that will receive the therapeutic benefit for the treatment of neurodegenerative and neurodevelopmental diseases. Its necessary compound ANAVEX 2-73 is being developed to treat Alzheimer's disease, Parkinson's disease, and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder. The company's operating segment is into developing novel therapies for the management of CNS diseases. |